The opportunity within the regulatory T-cell therapies market is projected to grow at an annualized rate of ~45%, till 2035

Health & Fitness / car-treg therapy, regulatory t-cell culture, Regulatory t-cell therapy, treg cell therapies companies / By /

reg based therapies have become a research hotspot in the field of immunotherapy due to their ability to prevent / delay graft rejection and control autoimmune responses generated post adoptive transfer in vivo

Advertisements

 

Roots Analysis has announced the addition of “Regulatory T-Cell (Tregs) Therapies Market” report to its list of offerings.

 

Given the various benefits offered, including high target specificity, customization potential and ability to generate immunological memory, regulatory T-cell (Treg) therapies have garnered significant attention among key industry stakeholders for the treatment of various oncological and non-oncological disease indications. Tregs have been observed to be capable of acting through more than one mechanism of suppression, depending on tissue site, type of cell and activation status of the target cell. In the future, high demand for personalized therapeutics with limited toxicity and high efficiency are likely to drive the growth of the Treg cell therapies market.

 

To order this 145+ page report, which features 90+ figures and 60+ tables, please visit “Regulatory T-Cell (Tregs) Therapies Market, 2021 – 2035”

 

Key Market Insights

 

Over 90 Treg cell therapies are being evaluated to target multiple target indications

Around 40% of the Treg cell therapies are in preclinical / discovery phase. Majority (49%) of these candidates are being developed for the treatment of oncological and autoimmune disorders. Further, most (81%) of the pipeline candidates are being evaluated as monotherapies, followed by those being developed in combination with other therapeutic agents (19%)

 

Presently, over 80 companies claim to be engaged in the development of Treg cell therapies

Majority of the firms (56%) are large companies, followed by small players (29%) and mid-sized (15%) firms. In addition, close to 65% of the stakeholders were established before 2000. Further, around 70% of the total firms are based in Asia Pacific and North America.

 

Over 180 clinical trials evaluating Treg cell therapies have been registered in the last two decades

Majority (57%) of the trials investigating Treg cell therapies are ongoing / planned. Further, over 70% of the total trials registered in this domain were / are being sponsored by governmental agencies, organizations and universities.

 

To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html

Key Questions Answered

 

  • What are the prevalent R&D trends related to Treg cell therapies?
  • Which are the key therapeutic areas currently being targeted by Treg cell therapies?
  • What are the key challenges faced by stakeholders engaged in this domain?
  • Who are the leading industry and non-industry players engaged in the development of Treg cell therapies?
  • What are the key geographies where research focused on Treg cell therapies is being conducted?
  • What are the key value drivers that are likely to influence the evolution of this upcoming market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

 

 

The research includes profiles of key players (listed below); each profile features a brief overview of the company, its financial performance (if available), recent developments and an informed future outlook.

  • Abata Therapeutics
  • Cellenkos
  • Coya Therapeutics
  • ILTOO Pharma
  • NEKTAR
  • Roche
  • Sonoma Biotherapeutics
  • TeraImmune
  • TRACT Therapeutics

 

For additional details, please visit

https://www.rootsanalysis.com/reports/regulatory-t-cell-therapies-market.html or email sales@rootsanalysis.com

You may also be interested in the following titles:

  1. CD47 Targeting Therapeutics Market: Industry Trends and Global Forecasts, 2021-2030
  2. Antibody Drug Conjugates Market (6th Edition): Industry Trends and Global Forecasts, 2021-2030

 

Contact Information

Roots Analysis Private Limited

Ben Johnson

+1 (415) 800 3415

+44 (122) 391 1091

Ben.johnson@rootsanalysis.com

 

Facebook – https://www.facebook.com/RootsAnalysis

LinkedIn – https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter – https://twitter.com/RootsAnalysis

Medium – https://medium.com/@RootsAnalysis

Pinterest – https://in.pinterest.com/RootsanalysisPin/_saved/

Quora – https://rootsanalysisinsights.quora.com/

Related Posts